Ernexa Stock Price, News & Analysis

Ernexa Therapeutics (Nasdaq: ERNA), a company developing cell therapies for cancer and autoimmune diseases, has completed the second closing of its securities purchase agreement, raising $6.0 million in gross proceeds through the issuance of 3,181,145 shares and 622,134 prefunded warrants.

Combined with the initial closing of $1.1 million in April 2025, total gross proceeds reach $7.1 million. The financing, approved by stockholders at the 2025 Annual Meeting, will support working capital needs and debt repayment. A remaining subscription amount of $190,248 for 121,255 shares is pending. The company recently implemented a 1-for-15 reverse stock split on June 12, 2025.

Ernexa Therapeutics (ERNA) announced a 1-for-15 reverse stock split effective June 12, 2025, aimed at regaining compliance with Nasdaq's $1.00 minimum bid price requirement. The company's 110,418,022 outstanding shares will be consolidated to approximately 7,361,201 shares. The split was approved by stockholders on June 2, 2025, and will not affect the total authorized shares or par value. No fractional shares will be issued, with stockholders receiving one whole share instead. Computershare will serve as the exchange agent, managing the conversion process for stockholders. This move, combined with recent financings and corporate restructuring, is part of Ernexa's strategy to strengthen its financial position and maintain capital market access for its clinical programs.

Ernexa Therapeutics (ERNA) will present new data at the ASCO Annual Meeting 2025 showcasing their innovative iMSC-based immunotherapy platform. The technology uses engineered mesenchymal stem cells (iMSCs) that secrete cytokines IL-7 and IL-15 directly into ovarian tumors. Key findings from the study demonstrate that these iMSCs, derived from adult skin cells, successfully:

- Migrated safely into tumor microenvironment
- Triggered strong immune activation
- Converted immunologically "cold" ovarian tumors into "hot" ones
- Significantly reduced tumor burden and extended survival in mouse models

The study, led by Dr. Michael Andreeff from MD Anderson Cancer Center, will be presented on June 2, 2025 in Chicago. The research validates Ernexa's platform technology and its potential to expand treatment options for patients with limited therapeutic choices.

Ernexa Therapeutics (NASDAQ: ERNA) has announced the formation of ErnexaTX2, a wholly owned subsidiary in Texas. This strategic move is designed to support the development of ERNA-101, the company's lead program targeting ovarian cancer. The subsidiary will facilitate ongoing research collaboration with Dr. Michael Andreeff from The University of Texas MD Anderson Cancer Center, an expert in cell therapy and tumor microenvironment.

The new Texas entity will help Ernexa build infrastructure for future clinical operations, including clinical manufacturing, regulatory interactions, and site activation. The company remains on schedule for IND-enabling studies in 2025, with first-in-human trials planned for 2026.

Ernexa Therapeutics (NASDAQ: ERNA) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference, scheduled for May 14, 2025, at The Plaza Hotel in New York City. The company's President & CEO, Sanjeev Luther, will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Attendees wishing to schedule meetings can contact John Perez at jperez@dboralcapital.com.

Ernexa Therapeutics presented groundbreaking data at the AACR Annual Meeting 2025 showcasing a novel stem cell therapy for ovarian cancer. The company's lead product, ERNA-101, uses engineered induced pluripotent stem cells (iPSCs) transformed into induced MSCs that secrete immune-boosting cytokines IL-7 and IL-15.

Led by Dr. Michael Andreeff from MD Anderson Cancer Center, the study demonstrated that these engineered cells effectively:

• Slowed tumor growth in ovarian cancer models
• Improved survival rates
• Increased presence of crucial immune cells (T cells, NK cells, macrophages)
• Enhanced T cell growth and multiplication
• Showed better growth and multiplication compared to traditional MSCs

This breakthrough addresses previous limitations of mesenchymal stem cells in cancer treatment, offering a more effective and scalable therapeutic approach. The results support continued development of Ernexa's cancer pipeline.

Ernexa Therapeutics (NASDAQ: ERNA) has announced new data presentation at the AACR Annual Meeting 2025 in Chicago, showcasing their lead cell therapy product ERNA-101. The study, led by Dr. Michael Andreeff from MD Anderson Cancer Center, explores a novel treatment for ovarian cancer using engineered cells that deliver therapy directly to tumors.

The technology works by secreting immune-stimulating cytokines to reshape the tumor microenvironment and enhance anti-tumor immune responses. The presentation will take place on Monday, April 28, 2025, from 2:00-5:00 pm CDT in the Immunology session, focusing on local treatments and novel delivery systems to manipulate tumor immunity.

Ernexa Therapeutics (NASDAQ: ERNA) has secured a new private placement agreement with accredited investors, raising approximately $7.25 million through the issuance of 69.3 million shares of common stock at $0.1046 per share. The funding will be executed in two phases:

- First closing on April 2, 2025: ~10.4 million shares issued for $1.1 million in gross proceeds
- Second closing pending stockholder approval at June 2, 2025 annual meeting

This financing follows a previous $5 million PIPE investment in 2024 and recent company rebranding. The funds will support Ernexa's strategic focus on developing cell therapies for advanced cancer and autoimmune disease, with emphasis on their ovarian cancer program.

Eterna Therapeutics has announced its rebranding to Ernexa Therapeutics (NASDAQ: ERNA), marking a strategic shift from a cell therapy platform to focused product development in ovarian cancer and autoimmune disease treatments. The company's technology specializes in transforming induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), which can target tumors and inflammation.

Two key products are currently in preclinical trials: ERNA-101, engineered to enhance immune response against cancer cells, specifically targeting ovarian cancer as its first indication, and ERNA-102, designed to combat inflammation and treat autoimmune disease. The company aims to address significant unmet needs, particularly in ovarian cancer treatment, where current platinum-based chemotherapy often faces resistance issues.